Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 321

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 321
---

CSO of Interpace Biosciences. Dr. Finkelstein serves as Diamir’s CLIA Medical Director.

<div align='center'>171</div>

Mikhail Denissenko, MD, PhD, Director, Program Management Hologic, Inc.Mikhail Denissenko has over 20 years of experience in Diagnostics and Drug Discovery. Most recently he
served as Director of Program Management at the Diagnostics Solutions division of Hologic, a medical technology company primarily focused
on improving women’s health through early detection and treatment. At Hologic, Dr. Denisenko oversaw a portfolio of new product
development projects encompassing molecular diagnostics of infectious diseases and cancer, including instrumentation. Previously, Dr.
Denissenko led New Product Portfolio Management at Prometheus Labs, a Nestlé Health Science Company that employed both Dx and Rx
approaches to improve human condition in gastrointestinal and liver diseases. Prior to Prometheus, Dr. Denissenko was a head of strategic
innovation, technology assessment, and product development for Molecular and Cellular Essentials business platform at Thermo Fisher Scientific;
was on Drug Discovery management team in the Pharmaceuticals division at Sequenom; and led an R&D group involved in the development
and production of commercial bioreagents at BD Biosciences. During his career in the life sciences industry, Dr. Denissenko had advanced
Product Lifecycle Management beyond being a mere toolset and established it as a key business approach, thus facilitating innovation and
driving product development. Dr. Denissenko is also a founder of two biotech startup companies and an author of over 40 peer-reviewed
publications, including a seminal Science paper (>1,960 citations), and several book chapters.

Kevin Krenitsky, MD.From
2015-2016, Kevin Krenitsky served as President of OpGen (NASDAQ:OPGN) and oversaw the rollout of the company’s Acuitas
MDRO family of Gene Tests and the development of Acuitas Lighthouse™ MDRO Management System. Dr. Krenitsky has more than 15 years
of experience leading and managing global diagnostic and biotechnology operations, including as Chief Commercial Officer & SVP of
International Strategy and previously Chief Operating Officer of Foundation Medicine (NASDAQ: FMI). Prior to Foundation Medicine, he
served as President of Enzo Clinical Labs, a wholly owned subsidiary of Enzo Biochem (NYSE:ENZ), where he instituted a comprehensive
strategic and operational plan that led to